Since cancer cells which become dependent on KRAS-driven metabolic adaptations also become sensitive to the inhibition of these routes [46], we tested the sensitivity of control and MutKRAS Huh28 cells to the PHGDH inhibitor NCT-503 [49] and found that KRASG12D expressing cells were indeed more sensitive to this drug (GI50 230 ± 5 vs 175 ± 4 μM, p < 0.05). This evidence concerns the gene KRAS and cancer.